What changed for Bipolar Disorder
A plain English summary of what recently moved in the public data Voxsanity tracks for Bipolar Disorder. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 3 to 2 (-1)
- Trials recruiting worldwide 159 to 157 (-2)
- Late-stage (Phase 3) trials 16 to 15 (-1)
- Trials on record 1,473 to 1,472 (-1)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Bipolar Disorder in July 2026. Voxsanity tracks 5 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 102 trials tracked for Bipolar Disorder that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03622749 · results posted 3 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 19 people in total across six groups. Each group received three different conditions in a set order — a "sham" (dummy/inactive) brain stimulation session, stimulation to a brain area called the VLPFC (ventrolateral prefrontal cortex), and stimulation to a brain area called the IPL (inferior parietal lobule). One participant did not complete the study, leaving 18 who finished. The trial was measuring how brain stimulation using a technique called TMS (transcranial magnetic stimulation, which uses magnetic pulses applie...
-
NCT05127837 · results posted 27 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05127837) compared two approaches to supporting people with psychosis-related experiences: a standard care approach called "Treatment as Usual" (TAU) and a digital tool called "CBTpro," which was designed to support a talking therapy known as CBT for psychosis. In total, 601 people took part across both groups — 285 in the TAU group and 316 in the CBTpro group. Each group included both clients (people receiving care) and providers (the clinicians supporting them). The trial tracked three things for the client participants:...
-
NCT04269772 · results posted 28 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04269772) involved 34 participants across three groups. Fifteen people took part in the "Community Treatment Adherence at Re-Entry" program (known as CARE), 15 received what is called "Treatment As Usual" (the standard care people would normally receive), and 4 were "Significant Others" — meaning close family members or support people involved in a participant's care. The trial was primarily measuring how satisfied participants were with their care, and also looked at self-reported ratings of depression and mania (a state...
-
NCT03825640 · results posted 28 January 2026
According to the results reported on ClinicalTrials.gov, this trial involved two groups: 12 people in the main participant group, called the Community Treatment Adherence at Re-Entry (CARE) group, and 6 people described as Significant Others (such as family members or close supporters). Of the 12 main participants, 11 completed the study, with 1 not finishing. The trial was measuring how acceptable and feasible a community-based treatment programme was for people returning to the community, as well as looking at self-reported scores related to depression and mania symptoms. The reported data...
-
NCT06041646 · results posted 2 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06041646) enrolled 29 adults who received a 180 microgram dose of a medicine called Igalmi (dexmedetomidine), which was placed under the tongue. Twenty-eight of the 29 participants completed the study, with one person not finishing. The trial was measuring changes in agitation levels using two main rating scales — one called the PEC (which scores agitation-related behaviours from 5, meaning no agitation, up to 35, meaning extremely severe agitation) and another called the CGI-I (which rates overall improvement from 1, mean...
-
NCT04063384 · results posted 19 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people across four groups, who were each assigned to drink either alcohol or a placebo (non-alcoholic) drink on different visit days. Two of the groups were described as "binge drinkers" (BD) and two as "typical drinkers" (TD). The trial was measuring two main things: how intoxicated participants felt after drinking (using a self-reported feelings survey called the SEAS), and how activity patterns between different regions of the brain changed while participants looked at emotional images during their drink session...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05445466 · results posted 6 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 14 people in total, split across three groups: 5 people received a type of brain stimulation called HD-tDCS, 4 received HD-tACS tuned to an "alpha" frequency (10 Hz), and 5 received a personalised form of HD-tACS tuned to each person's own "beta-gamma" brain frequency. The trial was measuring symptoms of mania — an elevated or unusually energised mood state — using two rating tools: one completed by a clinician (the YMRS, scored 0–60) and one filled in by the participants themselves (the ASRM, scored 0–20). Measuremen...
-
NCT02600494 · results posted 3 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02600494) enrolled 554 people across three groups: one group received a lower dose of lumateperone (28 mg), another received a higher dose (42 mg), and a third received a placebo (a dummy treatment with no active ingredient). The trial had two parts. In Part A, all three groups took their assigned treatment for six weeks in a blinded fashion, meaning participants did not know which treatment they were receiving. In Part B, a six-month open-label extension, only participants from the 42 mg lumateperone group continued, and...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00288353 · results posted 2 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 48 people in total — 25 in the aripiprazole (Abilify) group and 23 in the ziprasidone (Geodon) group. Of those, 18 and 16 people respectively completed the study, with 7 from each group not finishing. The trial was measuring changes in blood fat levels — specifically a ratio comparing triglycerides (a type of fat in the blood) to HDL ("good" cholesterol) — as well as body weight, BMI (a measure of body size based on height and weight), total cholesterol, HDL cholesterol, and triglycerides on their own. The reported d...
-
NCT05328297 · results posted 11 July 2025
According to the results reported on ClinicalTrials.gov, this trial tested an investigational drug called JNJ-55308942 against a placebo (an inactive look-alike treatment) in people with bipolar depression. A total of 116 people were enrolled — 55 in the JNJ-55308942 group and 61 in the placebo group. Of those, 54 and 60 respectively actually received a treatment. By the end of the study, 42 people in the JNJ-55308942 group and 50 in the placebo group completed it. The trial's main goal was to measure changes in depression severity over six weeks using a standard clinician-rated questionnaire...
-
NCT04211961 · results posted 29 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04211961) enrolled 50 people in total — 24 received a placebo (an inactive infusion) and 26 received scopolamine (a drug given by drip into a vein). Three people in the scopolamine group did not complete the study, while everyone in the placebo group finished. The trial was measuring symptoms of depression using two standard rating scales: the Hamilton Depression Rating Scale (scored 0–54, where higher numbers mean more severe symptoms) and the Montgomery-Åsberg Depression Rating Scale (scored 0–60, again with higher numbe...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03953417 · results posted 24 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03953417) enrolled 7 participants, all of whom completed the study with no drop-outs. The trial was testing a brain stimulation technique called Accelerated Intermittent Theta Burst Treatment — a type of non-invasive magnetic brain stimulation delivered in a faster-than-usual schedule. The main thing being measured was how scores on a depression rating scale (called the MADRS) changed from the start of the trial to the end. A secondary measurement tracked a mania rating scale (called the YMRS), which looks at symptoms like...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05228457 · results posted 12 March 2025
According to the results reported on ClinicalTrials.gov, this trial involved 26 people in total — 13 in each group. One person from each group did not finish the study, leaving 12 completers in each group. The trial was looking at a brain stimulation technique called Transcranial Magnetic Stimulation (TMS), where one group received real ("active") stimulation and the other received a fake ("sham") version that mimicked the experience without delivering the actual stimulation. The main thing being measured was depression symptom scores using a standard rating tool called the Montgomery-Åsberg D...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05227209 · results posted 21 February 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 64 people, all of whom received a study medication called SEP-4199 CR. The trial was an open-label study, meaning all participants knew they were receiving the drug, and it ran for up to 12 months. The main things the trial was measuring were how many participants experienced unwanted health events (called adverse events) during the study. Secondary measurements looked at changes in depression symptom scores over time using two standard rating tools used by clinicians. The reported data shows that of the 64 people wh...
-
NCT03360942 · results posted 12 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03360942) followed five people who already had a deep brain stimulation (DBS) device implanted — a device that delivers small electrical signals to specific areas of the brain — as a treatment for depression. The trial tracked these participants over time, checking in every 12 months to see whether their device was still working and to measure their depression symptoms using several standard rating scales. The reported data shows that none of the five participants formally "completed" the study as defined by the trial prot...
-
NCT04526067 · results posted 5 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04526067) enrolled 56 people in total — 35 in a group called R-CAT (a remote version of the programme) and 21 in a group called CAT (Cognitive Adaptation Training, delivered in person). All 56 participants who started the trial completed it. The trial was measuring three main things: how many people dropped out of the programme early, how well participants took their prescribed medication, and how their day-to-day social and work functioning changed over six months. The reported data shows that in the R-CAT group, 4 out o...
-
NCT01479829 · results posted 9 April 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 65 people in total — 35 in the intervention group and 30 in the control group. By the end of the study, 27 people in the intervention group and 20 in the control group had completed it, meaning 8 and 10 people respectively did not finish. The trial was measuring two things related to depression symptoms, both assessed using a questionnaire called the Hamilton Depression Rating Scale (HDRS-17). This is a clinician-administered tool where scores range from 0 to 54, with higher scores meaning more severe depression sympt...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03573297 · results posted 28 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03573297) looked at a medication called cariprazine in people with bipolar disorder. The trial had two main stages. In the first, open-label stage (where everyone knew what they were receiving), 896 people started taking cariprazine and 440 completed it. Those who responded well were then moved into the second, double-blind stage (where neither participants nor doctors knew who was getting which treatment). In that stage, 440 people were randomly assigned to one of three groups: a dummy pill (placebo, 145 people), caripraz...
-
NCT04276883 · results posted 11 September 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 380 adults across three groups: one group received a 180-microgram dose of the study treatment, another received a 120-microgram dose, and a third received a placebo (an inactive treatment). The trial was measuring changes in agitation levels using a standard rating scale called the PEC (Positive and Negative Syndrome Scale – Excited Component). This scale scores five signs of agitation — such as hostility, tension, and poor impulse control — on a range from 5 (no agitation) to 35 (extremely severe agitation). The vas...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03208036 · results posted 21 December 2022
According to the results reported on ClinicalTrials.gov, this trial looked at a brain stimulation technique called tDCS (transcranial direct current stimulation) compared to a "sham" (inactive/pretend) version of the same procedure. The trial enrolled 22 people in total — 11 in the tDCS group and 11 in the sham group — though numbers dropped over time due to people not completing each stage. By the final check-in at around five and a half months, 5 people in the tDCS group and 4 in the sham group had completed that stage. The trial was measuring several aspects of memory and thinking, as well...
-
NCT02188121 · results posted 22 November 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 204 people in total — 99 in a group that received a statin and/or a blood-pressure-lowering medicine called an angiotensin receptor blocker, and 105 in a "usual treatment" group who received their normal care. The trial was measuring whether people at risk of heart disease were receiving what the researchers defined as adequate cardiovascular prevention care — specifically, whether they were taking both a statin (a cholesterol-lowering medicine) and an angiotensin medication (a blood-pressure medicine). By the end of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02374476 · results posted 1 November 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 145 patients in an initial phase where an abnormal heart rhythm called ventricular tachycardia (VT — a fast, potentially dangerous heartbeat starting in the lower chambers of the heart) was tested and mapped. After that, 49 patients went into a "Bipolar Ablation" group (a specific catheter-based procedure using two points to deliver energy to the heart to try to correct the abnormal rhythm) and 60 patients were placed in a comparison "Registry" group. The trial's main goal was to measure how many people in...
-
NCT02527564 · results posted 6 October 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02527564) looked at a sleep medicine called suvorexant and measured how it affected total sleep time in people with insomnia. The trial had two phases: a one-week double-blind phase (where neither participants nor researchers knew who was getting the real medicine or a dummy pill called a placebo), and a three-month open-label phase (where everyone knew they were receiving suvorexant). In the double-blind phase, 23 people were assigned to suvorexant and 25 to placebo, with 22 and 24 completing that phase respectively. In t...
-
NCT03156504 · results posted 15 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03156504) involved 75 people who received ketamine infusions. One person did not complete the trial, leaving 74 who finished. The study was measuring two things 24 hours after a participant's third ketamine infusion: firstly, how many people reached a score on a depression rating scale (called the MADRS, which runs from 0 meaning no depression to 60 meaning very severe depression) that fell at or below 9, a level the researchers defined as remission; and secondly, how many people saw their scores on a suicidal thoughts rat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02090634 · results posted 27 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02090634) involved 58 people in total — 30 in a group that received personalised reminder text messages along with psychoeducation (called iTAB), and 28 in a group that received psychoeducation only (the control group). The trial was measuring how consistently participants took their HIV and psychiatric (psychotropic) medications, using a special electronic bottle cap system (called MEMS) that recorded each time a medication bottle was opened. By the end of the study, 25 people in each group had completed it. The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02363738 · results posted 28 July 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people in total — 29 received infliximab (an anti-inflammatory medicine given by drip) and 31 received a saline (salt water) placebo. The trial was looking at people with depression, and the main thing it was measuring was depression symptom severity using a tool called the Montgomery-Åsberg Depression Rating Scale (MADRS), where scores run from 0 to 60 and higher scores mean worse symptoms. The trial checked scores at the start, at 6 weeks, and at 12 weeks. Not everyone finished the trial — 21 people in the inflix...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03507036 · results posted 3 December 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03507036) enrolled 20 participants in a single treatment group, of whom 15 completed the study and 5 did not. The trial was measuring several physical characteristics of the skin around the knee area, including how loose or textured the skin appeared in photographs, how thick the outer and inner layers of skin were, how much water the skin was losing through its surface, how elastic (stretchy) the skin was, and how blood was flowing through the skin. These measurements were taken at the start of the study (called "baseline...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00961961 · results posted 19 October 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 177 people in its first phase, all of whom received lithium together with fluoxetine (an antidepressant). Of those 177, 51 completed the first phase and went on to a second phase, where they were randomly assigned to continue with either lithium plus fluoxetine (29 people) or lithium plus a placebo — a dummy pill with no active ingredient — (22 people). The trial was measuring whether participants experienced a return of a major depressive episode over the following year, and also whether anyone developed manic or hyp...
-
NCT01869374 · results posted 19 June 2020
According to the results reported on ClinicalTrials.gov, this trial compared two treatments for depression: Magnetic Seizure Therapy (MST) and Right Unilateral Electroconvulsive Therapy (RUL ECT, a form of electric shock therapy). A total of 18 people took part — 9 in each group. All 9 participants in the MST group completed the trial, while 8 of the 9 in the RUL ECT group completed it (one person did not finish). The trial was measuring changes in depression symptoms using a standard questionnaire called the Hamilton Rating Scale for Depression (24-item version), which gives scores ranging fr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03257865 · results posted 2 January 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03257865) compared brexpiprazole against a placebo (a dummy treatment with no active ingredient) in people experiencing manic symptoms associated with bipolar disorder. A total of 163 people were assigned to the brexpiprazole group and 170 to the placebo group at the start of the trial. Of those, 128 and 135 people respectively completed the study. The trial's main focus was on measuring changes in manic symptoms over three weeks using a standard rating tool called the Young Mania Rating Scale (YMRS), which scores symptoms...
See all 102 reported results for Bipolar Disorder
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding is currently directed toward Bipolar Disorder, and the level of that investment has remained broadly steady from year to year. This consistency suggests that Bipolar Disorder is seen as an ongoing research priority rather than a fleeting area of interest. For patients, a stable and meaningful level of funding generally...
See the full Bipolar Disorder page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.